logo
  

WHO Issues Updated Emergency Use Listing For Novavax's Nuvaxovid COVID-19 Vaccine

The World Health Organization or WHO has issued an updated Emergency Use Listing for Nuvaxovid (NVX-CoV2373) COVID-19 vaccine for active immunization to prevent COVID-19 caused by the SARS-CoV-2 as a primary series of two doses in adolescents aged 12 through 17 and as a booster in adults aged 18 and older, Novavax Inc. (NVAX) said in a statement.

Nuvaxovid (NVX-CoV2373) is a protein-based vaccine engineered from the genetic sequence of the first strain of SARS-CoV-2.

In the 12 through 17-year-old population, Novavax' vaccine has been authorized in more than 10 markets including the U.S., the European Union, and the U.K. The vaccine has also been authorized as a booster in the U.S., EU, Japan, Australia, New Zealand, and Switzerland, and a number of other countries have policy recommendations allowing use of the vaccine as a heterologous or homologous booster dose.

The WHO previously granted EUL for Nuvaxovid in adults aged 18 and older in December 2021.

For More Such Health News, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Health insurer Humana Inc. reported Wednesday a net loss for the fourth quarter that slightly widened from last year, hurt primarily by charges associated with productivity initiatives, despite 6.6 percent revenue growth. Adjusted earnings for the quarter topped analysts' expectations, while quarterly revenues missed it by a whisker. South Plainfield, New Jersey-based Two Rivers Coffee is recalling its peanut butter single serve hot chocolate pods citing an undeclared peanut allergen, the U.S. Food Drug Administration said. The recall involves peanut butter single serve hot chocolate pods distributed as "Brooklyn Bean Peanut Butter Cup Hot Cocoa", "Pingo Peanut Butter Cookie Hot Chocolate" and ... Shares of Novartis AG were losing around 2 percent in the early morning trading in Switzerland after the drug major reported Wednesday sharply lower profit in its fourth quarter with weak sales as well as the absence of prior year's hefty Roche income. Adjusted earnings, however, topped market estimates, while top line missed their view. Further, the company announced higher dividend...
Follow RTT